We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers established in New Jersey and Hangzhou. With a strategic emphasis on oncology, we have identified and developed a robust pipeline of six drug candidates.
We have assembled a management team and a scientific advisory board with industry leaders and influential scientists, who provide international and strategic guidance to our R&D, business development, and operational teams. In addition to building our own R&D capabilities, we continue to seek and secure partnerships with leading multi-national pharmaceutical companies such as Eisai Co., Ltd. or Eisai and Novartis Pharma AG or Novartis, to fully realize the potential of our pipeline programs. We are committed to becoming an innovative biotechnology company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform deadly cancer into a chronic and eventually curable disease.